Market Update (NYSE:MRK): Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination With Merck’s Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab)

[Marketwired] – Dynavax Technologies Corporation today announced that it has initiated patient dosing in the company’s trial evaluating the combination of two immunotherapies: Dynavax’s SD-101 and Merck’s KEYTRUDA® . … Read more on . . . → Read More: Market Update (NYSE:MRK): Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination With Merck’s Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab) Similar Articles: Market Update (NYSE:MRK): European Commission Approves Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma Stock Update (NYSE:MRK): New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status Company Update: Merck & Co Inc (NYSE:MRK) – 2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.